2018-11-04T00:00:00.000+08:00

[177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

[177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
The Lancet Oncology, volume: Jun; 19(6), pages 825-833
https://pubmed.ncbi.nlm.nih.gov/29752180/
Theranostics